Dhaval Mehta, MD

Articles by Dhaval Mehta, MD

A panel of 4 experts on multiple myeloma seated at a long table

Future Perspectives and Unmet Needs in Multiple Myeloma

ByKathleen Dorritie, MD,Joseph Franz, MD,Dhaval Mehta, MD,Christina Waters, PA-C

December 27th 2023

The expert panel concludes their discussion by examining the unmet needs and future for the treatment landscape in multiple myeloma.

Bispecific Antibody Selection in Multiple Myeloma

ByKathleen Dorritie, MD,Joseph Franz, MD,Dhaval Mehta, MD,Christina Waters, PA-C

December 27th 2023

Clinical insights on selecting the right bispecific antibody for the right patient and an overview of barriers seen in community practice.

Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma

ByKathleen Dorritie, MD,Joseph Franz, MD,Dhaval Mehta, MD,Christina Waters, PA-C

December 20th 2023

An overview of bispecific antibodies available for the treatment of patients with relapsed/refractory multiple myeloma.

Emerging Research in CAR T-Cell Therapy in R/R Multiple Myeloma

ByKathleen Dorritie, MD,Joseph Franz, MD,Dhaval Mehta, MD,Christina Waters, PA-C

December 20th 2023

A panel of multiple myeloma specialists discuss emerging data and ongoing research that are informing treating paradigms for patients with multiple myeloma.

Later-Line Therapy in Multiple Myeloma

ByKathleen Dorritie, MD,Joseph Franz, MD,Dhaval Mehta, MD,Christina Waters, PA-C

December 13th 2023

The expert panel provides clinical insights on the role of CAR T-cell therapy and factors that influence treatment selection in the second line and beyond.

Treatment Decision-Making and Assessing Frailty in Multiple Myeloma

ByKathleen Dorritie, MD,Joseph Franz, MD,Dhaval Mehta, MD,Christina Waters, PA-C

December 13th 2023

Multiple myeloma specialists outline frailty assessment practices and discuss how frailty informs treatment decisions.

Multiple Myeloma: Treatment Considerations and Role of MRD

ByKathleen Dorritie, MD,Joseph Franz, MD,Dhaval Mehta, MD,Christina Waters, PA-C

December 6th 2023

The panel discusses the effect minimal residual disease (MRD) has on treatment selection and provides insights on the treatment of younger patients with standard risk.